CLINICAL TRIALS PROFILE FOR ANIFROLUMAB

All Clinical Trials for anifrolumab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02446899 ↗	Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus	Completed	PRA Health Sciences	Phase 3	2015-07-09	The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
NCT02446899 ↗	Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus	Completed	AstraZeneca	Phase 3	2015-07-09	The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
NCT02446912 ↗	Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus	Completed	PRA Health Sciences	Phase 3	2015-06-09	The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
NCT02446912 ↗	Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus	Completed	AstraZeneca	Phase 3	2015-06-09	The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
NCT02547922 ↗	Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis	Completed	Parexel	Phase 2	2015-11-04	The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).
NCT02547922 ↗	Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis	Completed	AstraZeneca	Phase 2	2015-11-04	The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).
NCT02601625 ↗	A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects	Completed	AstraZeneca	Phase 1	2015-11-16	This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects

Clinical Trial Conditions for anifrolumab

Condition Name

Condition Name for anifrolumab
Intervention	Trials
Systemic Lupus Erythematosus	4
Active Systemic Lupus Erythematosus	4
Lupus Nephritis	2
Safety	1

Condition MeSH

Condition MeSH for anifrolumab
Intervention	Trials
Lupus Erythematosus, Systemic	9
Nephritis	2
Lupus Nephritis	2
Skin Manifestations	1

Clinical Trial Locations for anifrolumab

Trials by Country

Trials by Country for anifrolumab
Location	Trials
United States	125
Germany	7
Korea, Republic of	6
Hungary	6
Poland	6

Trials by US State

Trials by US State for anifrolumab
Location	Trials
New York	8
Florida	7
California	7
Georgia	7
Oklahoma	6

Clinical Trial Progress for anifrolumab

Clinical Trial Phase

Clinical Trial Phase for anifrolumab
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	4
Phase 1	3

Clinical Trial Status

Clinical Trial Status for anifrolumab
Clinical Trial Phase	Trials
Completed	5
Recruiting	5
Not yet recruiting	4

Clinical Trial Sponsors for anifrolumab

Sponsor Name

Sponsor Name for anifrolumab
Sponsor	Trials
AstraZeneca	12
PRA Health Sciences	3
Parexel	2

Sponsor Type

Sponsor Type for anifrolumab
Sponsor	Trials
Industry	19
Other	6
NIH	1